Montserrat M. M.
- Country
- Spain
- Department
- Oncology
Research Overview
Data & Insights
Has run more than one trial at 2 of 27 partner sites.
Specializations
Breast Cancer Therapeutics
Focused on hormone‑receptor‑positive and HER2‑negative disease as well as HER2‑low and triple‑negative subtypes.
- Estrogen Receptor‑Positive HER2‑Negative Advanced Breast Cancer
- HR+/HER2‑Negative Metastatic Breast Cancer
- Triple‑Negative Breast Cancer with brain metastases
- HER2‑Low Breast Cancer in older patients
Investigations include novel endocrine combinations, antibody‑drug conjugates and targeted kinase inhibitors.
Lung Cancer and Thoracic Oncology
Encompasses both small‑cell and non‑small‑cell histologies, including molecularly defined subsets.
- Small Cell Lung Cancer (second‑line and beyond)
- Non‑Small Cell Lung Cancer with brain metastasis
- KRAS G12C‑mutant NSCLC
- EGFR‑mutated NSCLC with uncommon exon 20 insertions
Research addresses immunotherapy, targeted agents and combination regimens for resistant disease.
Hematologic Malignancies
Targets a spectrum of lymphoid and myeloid neoplasms, with emphasis on relapsed or refractory settings.
- Acute Myeloid Leukemia (including high‑risk MDS)
- Multiple Myeloma (newly diagnosed and relapsed)
- Diffuse Large B‑Cell Lymphoma (R‑CHOP‑eligible)
- Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Studies explore novel monoclonal antibodies, cellular therapies and pathway inhibitors.
Hepatobiliary and Gastrointestinal Oncology
Addresses primary liver malignancies and biliary tract cancers, often with advanced presentation.
- Hepatocellular Carcinoma (unresectable, non‑transplant candidates)
- Cholangiocarcinoma (intra‑ and extra‑hepatic)
- Gastric and Gastroesophageal Junction Adenocarcinoma with HER2 expression
- Pancreatic Ductal Adenocarcinoma (metastatic)
Therapeutic focus includes checkpoint inhibition, targeted kinase blockade and antibody‑drug conjugates.
Rare and Emerging Oncology Indications
Includes ultra‑rare malignancies and novel molecular targets that lack standard therapies.
- Neuroendocrine Tumors with atypical mutations
- Nontuberculous Mycobacterial lung infection in immunocompromised oncology patients
- AL Amyloidosis associated with plasma cell dyscrasias
- Vascular Tumors expressing Nectin‑4
Efforts aim to define biomarker‑driven strategies and assess innovative therapeutic platforms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.